Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Successfully completing recruitment in an early Alzheimer’s disease study
91黑料 conducted a phase 3 multicentre, randomised, double-blind, placebo-controlled study of the efficacy, safety and biomarker effects of a compound in patients with early Alzheimer’s disease (AD) and APOE4/4 Genotype. The study encompassed 99 sites in 9 countries in the US and Europe.
Navigating complexity to achieve clinical trial success
91黑料 is conducting a global, phase 1/2a clinical trial for a small biotech company to evaluate potential treatment for Parkinson disease (PD).
Collaboration accelerates rare disease trial delivery
How commitment to partnership overcame historical, layered operational challenges.
Increased compliance for complex Alzheimer’s disease study
The sponsor in this case was a large pharmaceutical company that contracted 91黑料 to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.
Multinational phase 1 biosimilar study
91黑料 conducted a multinational biosimilar phase 1 study for multiple sclerosis (MS). This trial was performed under high regulatory scrutiny and challenging pandemic conditions, with increased dosing targets requiring additional site activation.
Exceeding recruitment timelines
91黑料 was awarded a global study for Major Depressive Disease (MDD) in over 600 adult subjects. Enrollment began during the COVID pandemic and despite challenging protocol requirements, IMP expiry date and database lock requirements, 91黑料 reached LPR and DBL closed five months early.
Overcoming recruitment challenges
91黑料 successfully overcame site activation and patient recruitment challenges in an early Parkinson’s disease (PD) study.
ALS trial best practices ensure success amid recruitment challenges
A pharmaceutical sponsor contracted 91黑料 to run a phase 3 trial for an amyotrophic lateral sclerosis (ALS) treatment that included a large patient population spanning 14 countries.